Robbins Geller files suit against Rocket Pharma over undisclosed trial risks tied to RP-A501. Lead plaintiff deadline: August ...

Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy RP-A701 is a first-in-class gene therapy for the treatment of BAG3 ...

CRANBURY, N.J., June 30, 2025--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...

The Rocket Pharmaceuticals, Inc. (RCKT) Securities Class Action: The litigation focuses on the propriety of Rocket Pharmaceutical’s disclosures about the trial protocol being implemented in the ...

Investing.com -- Rocket Pharmaceuticals Inc (NASDAQ: RCKT) stock rose 2.4% after the company announced it received clearance from the U.S. Food and Drug Administration for its Investigational New ...

The Rocket Pharmaceuticals, Inc. (RCKT) Securities Class Action: The litigation focuses on the propriety of Rocket Pharmaceutical's disclosures about the trial protocol being implemented in the RP ...

The lawsuit comes after investors saw the price of their shares in Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) crash over 60% on May 27, 2025 as a result of the company’s announcement that the ...

Rocket Pharmaceuticals, Inc. (RCKT) Faces Securities Class Action Amid Protocol Change and FDA’s Clinical Hold on Gene Therapy Trial - Hagens Berman ...

Shares of Rocket Pharmaceuticals Inc (NASDAQ:RCKT) advanced 2.4% after the company announced that the U.S. Food and Drug ...